Editas Medicine Option Alert: Aug 21 $45 Calls at the Ask: 1171 @ $0.3 vs 11933 OI; Earnings 8/6 After Close Ref=$30.4135
Benzinga · 9小时前
Earnings Preview: Editas Medicine (EDIT) Q2 Earnings Expected to Decline
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 4天前
Editas taps Catalent to supply lineup of products
Seeking Alpha · 5天前
Catalent Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine Pipeline
CAMBRIDGE, Mass. and SOMERSET, N.J., July 29, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions
GlobeNewswire · 5天前
If You Invested $100 in CRISPR Therapeutics' IPO, This Is How Much Money You'd Have Now
MotleyFool.com · 07/26 12:10
Gene Therapy Companies Are Racing to Cure Sickle Cell. That Would Open the Door to Curing Dozens of Other Diseases.
Successful treatments would demonstrate the potential for gene therapy—and boost a number of biotech companies.
Barrons.com · 07/25 15:52
Could Editas Medicine Be a Millionaire-Maker Stock?
CRISPR gene editing became a big story around 2012, and in the few years that followed, the promise of the technology spurred the founding of several biotechs focused on using it to treat diseases. Editas Medicine (NASDAQ: EDIT) was one of them. Since its IP